The Systemic Poisoning and Murder of 40,000 American Veterans During the COVID-19 Pandemic

By Staff Writer

December 29, 2025

This report has two principal objectives:

1) inform the public, members of the US Congress (MOCs), and other federal officials about the poisoning* and subsequent murders of upwards of 40,000 American military veterans during the COVID-19 pandemic; and

2) cause MOCs and other federal officials to seriously investigate these alleged murders that occurred during the operation of a nationwide illegal criminal enterprise (explained herein) in violation of the federal Racketeer Influenced and Corrupt Institution (RICO) Act of 1970.

It is anticipated that a thorough investigation via congressional hearings and a Department of Justice (DOJ) criminal investigation will reveal a pattern of racketeering activity and intentional harm perpetrated against those who served our nation.

The COVID-19 Narrative: A Reckoning?

READ MORE: Chronology of Deep state Assets executed by the US military (Part XXIV – Anthony Fauci)

Tragically, highly effective, low cost, life-saving alternative treatments for the COVID virus such as Ivermectin and Hydroxychloroquine were routinely denied by hospital physicians and other health care officials.

Some say the denial of these life-saving treatments amounts to premeditated murder.

Public testimony of US Health and Human Services Secretary Robert F. Kennedy Jr and Dr David Martin…

RFK Jr. Accuses Fauci of Knowing Remdesivir Was Lethal – A Deep Dive

WATCH: Died Suddenly on X: “RFK Jr: “tony Fauci KNEW that Remdesivir would kill you” Yet, another reason why Anthony Fauci belongs in federal prison. / X

A critical question that must be asked is why did hundreds of thousands of patients receive a drug that, according to Robert F. Kennedy Jr., Anthony Fauci knew was likely to cause death? This accusation, recently highlighted by the “Died Suddenly” account on X (formerly Twitter), centers around Remdesivir, an antiviral medication used during the COVID-19 pandemic.

The claim isn’t new, but it’s gaining renewed traction as scrutiny of the pandemic response intensifies. RFK Jr. alleges Fauci knowingly pushed Remdesivir despite evidence suggesting its harmful effects. This assertion stems from pre-pandemic research and animal trials that indicated potential for toxicity.

Remdesivir’s efficacy was, and remains, a contentious issue.while initially touted as a potential treatment, subsequent studies, including the World Health Organization’s SOLIDARITY trial, showed it had little to no effect on mortality. Though, it continued to be used, particularly in hospitals, frequently enough as part of standard treatment protocols.

The core of the controversy lies in the risk-benefit analysis. Did the potential, albeit limited, benefits of Remdesivir outweigh the known risks, especially given the concerns raised by pre-clinical data? And, crucially, was this information fully and transparently communicated to both doctors and patients?

Fauci and proponents of Remdesivir argue that the drug was used in a context of desperate need, with limited treatment options available. they maintain that the available data, at the time, supported its use, and that it was a reasonable attempt to combat a novel and deadly virus.

However, critics point to the financial incentives at play. Gilead Sciences, the manufacturer of Remdesivir, stands to profit significantly from its sales. Questions have been raised about the influence of pharmaceutical lobbying and the potential for bias in research and recommendations.

The accusation leveled by RFK Jr. is serious, calling for criminal charges against a prominent figure in the public health establishment. It underscores the deep distrust that has emerged regarding the handling of the COVID-19 pandemic and the need for a thorough and impartial investigation into all aspects of the response.

The Remdesivir Revelation: A Legal Case for Accountability

WATCH: Dr Peter McCullough – Remdesivir

The legal brief developed and sent to the above officials was on behalf of the aggrieved families of 46 Texans (victims) who perished in Texas hosp**

Allegations of a Nationwide Criminal Enterprise and the Use of Remdesivir During the COVID-19 Pandemic

A legal brief alleges the existence of a nationwide criminal enterprise responsible for a staggering number of deaths – an estimated 40,000 military veterans and up to 900,000 non-veteran victims. This enterprise, it is claimed, operated through a coordinated effort involving government officials, healthcare administrators, and a pharmaceutical company.

The core of the allegation centers around the drug Remdesivir,manufactured by Gilead Sciences,Inc., and its widespread use in US hospitals during the COVID-19 pandemic. Accusations state that Remdesivir was administered to patients despite knowledge of its toxicity, leading to kidney and organ failure and ultimately, death.Specifically, it is indeed alleged that patients who refused the drug were sometimes given it without their consent.

The alleged criminal enterprise is comprised of several key groups:

1. Federal Officials: A group of colluders including current and former top officials from the Centers for Disease control (CDC), Centers for Medicare & Medicaid Service (CMS), National Institute of allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), and Federal Drug Administration (FDA).
2. Hospital Personnel: Hospital administrators and staff across the US who allegedly administered Remdesivir knowing its harmful effects.
3. Gilead Sciences,Inc.: The manufacturer of Remdesivir.
4. COVID-19 Patients: Those who received Remdesivir,particularly those administered the drug against their will,and subsequently died.

The allegations highlight several key events and practices:

* In April 2020, Dr. Anthony Fauci, then head of NIAID, declared Remdesivir would be “the standard of care” for COVID-19 patients, leading to its widespread adoption in hospital protocols.
* Despite a November 2020 suggestion from the World Health Organization (WHO) advising against the use of Remdesivir for COVID-19 treatment, its use continued in US hospitals through 2024.
* CMS allegedly provided substantial financial bonuses to hospitals for each dose of Remdesivir administered to COVID-19 patients, possibly acting as a coercive incentive.
* it is further alleged that high-ranking officials at the CDC, NIAID, FDA, and NIH received financial benefits linked to the widespread use of Remdesivir.

The criminal RICO statute carries severe penalties, including prison terms of up to 20 years and substantial financial penalties, with the added ability for prosecutors to seize assets to prevent their removal from the country. A complete list of accused individuals is available in the referenced texas legal brief.

The Rise of the Micro-SaaS: Building Small Businesses with Big Potential

For years, the tech world has been captivated by the allure of the “unicorn” – the billion-dollar startup poised to disrupt entire industries.But a quieter, more accessible revolution has been brewing: the rise of the micro-SaaS.

Micro-SaaS, short for “small Software as a Service,” refers to businesses built around a single software product, typically serving a niche market.Often run by a single founder or a very small team, these businesses generate modest but consistent revenue, offering a compelling alternative to the high-risk, high-reward world of venture-backed startups.

Why Micro-SaaS is Gaining Traction

Several factors are driving the growth of micro-SaaS:

* Lower Startup Costs: Unlike traditional SaaS companies that require meaningful capital for progress, marketing, and sales, micro-saas ventures can be launched with relatively little investment. Many founders leverage no-code tools and existing platforms to minimize development time and costs.
* Niche Focus: By concentrating on a specific problem for a well-defined audience, micro-saas businesses can achieve product-market fit more quickly and efficiently.This focused approach also reduces marketing expenses.
* sustainable Revenue: The subscription-based model of saas provides a predictable and recurring revenue stream,allowing founders to build a sustainable business without constantly chasing new customers.
* Lifestyle Freedom: Many micro-SaaS founders prioritize lifestyle freedom and flexibility. The smaller scale of these businesses allows them to maintain control and avoid the pressures of rapid growth and external investors.
* Accessibility: The barrier to entry is lower. You don’t need to be a coding expert to build and launch a successful micro-SaaS product, thanks to the proliferation of no-code and low-code tools.

Examples of Successful Micro-SaaS Businesses

The micro-SaaS landscape is diverse, encompassing a wide range of tools and services. Here are a few examples:

* Letterdrop: A simple newsletter tool for writers. (https://letterdrop.co/)
* Carrd: A one-page website builder. (https://carrd.co/)
* Tweet Hunter: A tool to help you find and schedule tweets. (https://tweethunter.io/)
* Simple Poll: Easily create polls for social media. (https://simplepoll.io/)

These businesses demonstrate that you don’t need a complex product or a massive team to build a profitable online venture.

Getting Started with Micro-SaaS

If you’re considering launching a micro-SaaS business, here are a few tips:

* Identify a Problem: Look for a specific pain point experienced by a niche audience.
* Validate Yoru Idea: Before investing significant time and resources, test your idea with potential customers.
* Choose the Right Tools: Leverage no-code and low-code platforms to accelerate development.
* Focus on Marketing: Target your marketing efforts towards your specific audience.
* Prioritize Customer Support: Excellent customer service is crucial for building loyalty and retaining subscribers.

The micro-SaaS movement is empowering a new generation of entrepreneurs to build sustainable,profitable businesses on their own terms. It’s a testament to the power of focusing on solving real problems for real people, and a compelling alternative to the traditional startup path.